Deanna L. Kirkpatrick

Davis Polk advised the representative of the several underwriters in connection with the initial public offering of 82,800,00 units of CC Neuberger Principal Holdings II, including 10,800…

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 4,000,000 shares of its common stock. The common stock is listed on the…

Davis Polk advised the representatives of the underwriters in connection with the $511.5 million SEC-registered offering of 5,500,000 American Depositary Shares of BioNTech SE. In addition,…

Davis Polk advised the sole book runner in connection with the initial public offering of 30,000,000 units of East Resources Acquisition Company for aggregate proceeds of $300 million. Each…

Davis Polk advised the underwriters in connection with the offering of $2 billion aggregate principal amount of 1.300% bonds due July 22, 2030, issued by the Province of Alberta. The…

Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by InflaRx N.V. of its shares of common stock for up to an aggregate amount of $50…

Davis Polk advised the representatives of the underwriters in connection with an initial public offering of Inventiva S.A.’s 7,478,261 American Depositary Shares. Aggregate gross…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $69 million follow-on offering of common stock of Magenta Therapeutics…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $650 million aggregate principal amount of 1.150% notes due 2028 and $650…

Davis Polk advised the underwriters in connection with the initial public offering of 51,750,000 units of Trebia Acquisition Corp., including 6,750,000 units purchased pursuant to the…